Endeavor BioMedicines inks $62m Series A

Endeavor BioMedicines, a developer of new treatments targeting the underlying causes of pulmonary fibrosis, has raised $62 million in Series A financing.

Endeavor BioMedicines, a developer of new treatments targeting the underlying causes of pulmonary fibrosis, has raised $62 million in Series A financing. The lead backers were Omega Funds, Longitude Capital and Endeavor’s management.

Source: Press Release